CNPV II: Secondary Indications Feature In Second Batch Of US FDA Voucher Winners

 
• By Ramsey Baghdadi
  
Will rapid reviews of secondary indications slide more easily into FDA’s workflow? (Shutterstock)

More from Approval Standards

More from Pathways & Standards